TI
OMED

Trexquant Investment’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History

Trexquant Investment’s Portfolio OMED Stock Details OMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-40,380
Closed -$372K – 1427
2017
Q1 		$372K Buy
+40,380
New +$355K 0.05% 658

Other funds holding OMED

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
IHM
Iguana Healthcare Management New York $152M AUM 48.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Trexquant Investment's OMED Position: Q2 2017 in Review

Trexquant Investment sold out of OncoMed Pharmaceuticals, Inc. (OMED) in Q2 2017, closing a stake of 40,380 shares — an estimated $372K sold.

Trexquant Investment first reported a position in OMED in Q1 2017 and held it in 1 quarter. The position peaked at $372K in Q1 2017. 68 funds tracked by Wall St. Rank hold OMED as of Q2 2017.

  • Trexquant Investment reported no remaining OncoMed Pharmaceuticals, Inc. position as of Q2 2017 after selling out during the quarter.
  • Trexquant Investment sold 40,380 OncoMed Pharmaceuticals, Inc. shares in Q2 2017, an estimated $372K.
  • Trexquant Investment first reported a position in OncoMed Pharmaceuticals, Inc. in Q1 2017 and held it in 1 quarter.
  • Trexquant Investment's OncoMed Pharmaceuticals, Inc. position peaked at $372K in Q1 2017.
  • 68 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q2 2017.

Based on Trexquant Investment's 13F filing for Q2 2017, filed 1 Aug 2017.